Statins reduce cardiovascular riskBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7354.5/a (Published 06 July 2002) Cite this as: BMJ 2002;325:5
- Susan Mayor
Treating patients at high risk of cardiovascular events with the HMG-CoA (hydroxymethyl glutaryl coenzyme A) reductase inhibitor simvastatin reduced the risk of myocardial infarction, stroke, and revascularisation by about one third, even in patients with normal or low blood cholesterol levels, according to the latest findings from the heart protection study published this week.
The study randomised 20536 adults with coronary disease, other occlusive artery disease, or diabetes to treatment with simvastatin (40 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial